| abstract |
Potential opioid receptor antagonists of formula (I) and their use as pharmacotherapy to treat depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates Is disclosed. Even more specifically, the present disclosure relates to potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds, and the use of those compounds to improve or treat addiction, eating disorders, etc. I will provide a. (1) |